News Biogen Inc.

Equities

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-16 pm EST			5-day change	1st Jan Change
171.50 ^USD	-2.41%		-2.47%	+12.15%

Dec. 12	Bitcoin hoarding company Strategy remains in Nasdaq 100	RE
Dec. 12	Nasdaq says Biogen, CDW Corporation, GlobalFoundries, Lululemon Athletica, On Semiconductor, Trade Desk will be removed from Nasdaq 100 index	RE

Bitcoin hoarding company Strategy remains in Nasdaq 100	Dec. 12	RE
Nasdaq says Biogen, CDW Corporation, GlobalFoundries, Lululemon Athletica, On Semiconductor, Trade Desk will be removed from Nasdaq 100 index	Dec. 12	RE
Morgan Stanley Adjusts Biogen Price Target to $156 From $149, Maintains Equalweight Rating	Dec. 12	MT
Alzheimer's drug hunt learns from cancer fight's multi-target playbook	Dec. 12	RE
Analysts flag risks for Strategy at Nasdaq 100 index reshuffle	Dec. 12	RE
PREVIEW-Analysts flag risks for Strategy at Nasdaq 100 index reshuffle	Dec. 12	RE
This Is Decision Day	Dec. 10
Wells Fargo Adjusts Price Target on Biogen to $190 From $155, Maintains Equalweight Rating	Dec. 10	MT
Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix…	Dec. 10
HSBC Downgrades Biogen to Reduce From Hold, Adjusts Price Target to $143 From $144	Dec. 10	MT
Biogen : “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List	Dec. 08	PU
Stoke Therapeutics, Inc. and Biogen Inc. Present Data That Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome	Dec. 05	CI
Stoke Therapeutics and Biogen present data that further support the disease-modifying potential of zorevunersen	Dec. 05	RE
Biogen and Stoke Therapeutics present data that further support the disease-modifying potential of zorevunersen	Dec. 05	RE
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting	Dec. 05	GL
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting	Dec. 05	AQ
Biogen Shares New Leqembi Data on Slower Alzheimer's Progression, Injection Option	Dec. 04	MT
Eisai Co., Ltd. and Biogen Inc. Present New Data	Dec. 03	CI
Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment	Dec. 03	RE
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025	Dec. 03	PR
Health Care Up on Alzheimer's Hopes - Health Care Roundup	Dec. 03	DJ
Biogen Inc. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-03-2025 11:30 AM	Dec. 03
Biogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer's Disease 2025 Conference	Dec. 02	MT
New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF	Dec. 02	PR
Eisai Co., Ltd. and Biogen Inc. Announces New Data Presented at the Clinical Trials on Alzheimer's Disease Conference 2025	Dec. 02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Biogen Inc.

Equities

BIIB

US09062X1037

Pharmaceuticals

Filters